Ezetimibe promotes CYP7A1 and modulates PPARs as a compensatory mechanism in LDL receptor-deficient hamsters

BACKGROUND: The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption. Recently, ezetimibe has been demonstrated to have reverse cholesterol transport (RCT) promoting effects in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Bin, Lin, Ping, Ji, Yubin, Yin, Jiayu, Wang, Jin, Yang, Xiaoqian, Li, Ting, Yang, Zixun, Li, Fahui, Guo, Shoudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007651/
https://www.ncbi.nlm.nih.gov/pubmed/32035489
http://dx.doi.org/10.1186/s12944-020-1202-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007651/
https://www.ncbi.nlm.nih.gov/pubmed/32035489
http://dx.doi.org/10.1186/s12944-020-1202-5

Ejemplares similares